Kamhada Dual, a biopharmaceutical company specializing in plasma-based products, reports today that it has signed agreements with two international pharmaceutical companies to distribute three biosimilar products in Israel. Subject to the approval of the products by the European Health Authority (EMA) and then by the Israeli Ministry of Health.
A biosimilar is an almost identical copy of a registered biological drug from another company. A biosimilar product is actually an approved version of the source drug, and it can get a permit from the regulatory authorities only when the patent of the original product has expired.
The three products are expected to be launched in Israel between the years 2022 and 2024. The two pharmaceutical companies will be responsible for the development, production and supply of the three products.
“These agreements expand the pipeline of biosimilar products to be distributed by us in Israel, which already includes six Elbotek products, and position Kamahda as a leader in the developing biosimilar market in Israel,” said Amir London, CEO of Kamhada.
“The Israeli market for innovative reference products, for which these three biosimilar products are intended, is estimated at a total sales range of between $ 20 million and $ 25 million in 2019, and we estimate the maximum total sales potential from the distribution of these three products, obtainable upon regulatory approval. And within a few years of launch, in the range of $ 5 million to $ 7 million per year.
These sales will be added to maximum sales from the sale of Albotech’s six products expected in the range of $ 20 million to $ 30 million, which are subject to EMA approval and then approval by the Israeli Ministry of Health are expected to be launched between 2022 and 2025. The expected future of sales and profitability in our distribution sector. “
Pimi Investment Fund is the main shareholder in Kamhada and holds approximately 21% of the company’s issued share capital.